More research is needed to understand the pathogenesis underlying this association.
Understanding the difference in biology and clinical presentations of cutaneous conditions in different skin types is critical for health care professionals to treat a diverse population.
Researchers have explored whether the adverse effects of tazarotene are exacerbated during the colder winter months and whether there is variation in treatment efficacy and tolerability between cold vs warm seasons.
Naiem Issa, MD, PhD, shared highlights from his sessions on the 1726 nm laser for acne, atopic dermatitis disease modification, advances in hidradenitis suppurativa, and microneedling techniques for vitiligo.
Stephen Tyring, MD, PhD, MBA, covers the burden of antimicrobial resistance and the need for alternative treatments.
In the final part of this Frontline Forum series, Brent Moody, MD; Sarah Arron, MD, PhD; Justine Cohen, DO; Emily Ruiz, MD, MPH; and Todd Schlesinger, MD, review 4 real-world clinical cases of BCC and the treatments they utilized.
Payers must make public the individual amounts their health plans pay providers across all types of services and locations, including hospitals, doctors’ offices, imaging centers, outpatient surgery centers and urgent care clinics.
In recent years, there has been a noticeable rise in diagnoses of sexually transmitted infections, often which present with skin findings.
Last week, the US Food and Drug Administration approved biosimilar ustekinumab-aekn (Selarsdi; Alvotech and Teva) for psoriasis and PsA.
Brandon Beal, MD shared his experience, which technology solutions work best, and resources available to dermatology practices.
Song stressed the need for careful therapy selection in patients with comorbid conditions to avoid exacerbating health issues.
How does a dermatologist go from the clinic to the television screen? Editorial Board member Will Kirby, DO, FAOCD, shares his thoughts about reality television and his appearance The Traitors.
The study found that white patients were offered access to patient portals more frequently than Black or Hispanic patients.
Medical practices can choose from a wide array of tools to enable communication with patients from diverse backgrounds.
In October's cover feature, Nicole A. Negbenebor, MD, FAAD, discusses the benefits of intralesional 5-fluorouracil injection for older patients with squamous cell carcinoma who may elect to delay therapy or are not ideal candidates for surgery.
Niacinamide is a versatile skincare ingredient that effectively targets acne, age-related issues, hyperpigmentation, and atopic dermatitis, writes Anjeza Fero, PharmD, RPh.
Researchers behind the latest benzene studies found no increased cancer risk with use of products containing benzoyl peroxide.
Luke Maxfield, DO, discusses the importance of understanding social media trends and engaging patients in dialogues.
Dr Darrel Rigel provides insights into cutting-edge photoprotection strategies, emphasizing the specific considerations for skin of color patients and the critical role of sunscreen in preventive dermatology.
The Omicron variant of COVID-19 is spreading quickly, jumping continents with infected travelers. Here’s the latest on what global health officials know about it.
Andrew Baker, MBA, MPAS, PA-C, discusses his role in skin cancer detection and advice for PAs interested in skin surgeries and Mohs closures.
In the final part of this Frontline Forum series, Brent Moody, MD; Sarah Arron, MD, PhD; Justine Cohen, DO; Emily Ruiz, MD, MPH; and Todd Schlesinger, MD, review 4 real-world clinical cases of BCC and the treatments they utilized.
Allergan Aesthetics recently announced the fifth-year of its partnership with Girls Inc. Nkem Ugonabo, MD, MPH, and Adelle Infante recently spoke with Dermatology Times to discuss the importance of STEM and dermatology mentorship.
Greater treatment costs are associated with more advanced stages of melanoma, particularly due to increasing prices of treatments.
Brett King, M.D, Ph.D and Alexandra Golant, M.D summarize their thoughts on optimizing treatment outcomes for patients suffering from atopic dermatitis with the JAK inhibitor class.